


06-16-06

IFW

Express Mail No.: EV 456 922 148 US



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application	Meijer <i>et al.</i>	Confirmation No.	8852
Serial No.	10/577,686	Art Unit	1626
Filed:	April 27, 2006	Examiner	To be Assigned
For:	INDIRUBIN-TYPE COMPOUNDS, COMPOSITIONS, AND METHODS FOR THEIR USE	Attorney Docket No.	11181-025-999

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.56

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and §1.97 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby direct the Examiner's attention to the references listed on the attached List of References Cited by Applicant.

Copies of publications A01-A09 listed on Form PTO-1449 are submitted herewith.

Identification of references listed on PTO Form 1449 is not to be construed as an admission of Applicants or attorneys for Applicants that such references are available as "prior art" against the subject application.

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.56

Serial No. 10/577,686

Page 2

Pursuant to 37 C.F.R. §1.97(b), since this information disclosure statement is being filed before the mailing of the first Office action on the merits, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Jones Day deposit account no. 50-3013 (referencing 409742-999023); a duplicate of this sheet is enclosed.

Respectfully submitted,

Date:

June 14, 2006

Roger C. Rich

For: Nikolaos C. George (Reg. No. 39,201)

JONES DAY

222 East 41st Street


New York, New York 10017

(212) 326-3939

54,398

(Reg. No.)

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)				ATTY DOCKET NO.		APPLICATION NO	
				11181-025-999		10/577,686	
				APPLICANT Meijer <i>et al.</i>			
				FILING DATE		GROUP	
				April 27, 2006		1626	
U.S. PATENT DOCUMENTS							
INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE



FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	A01	WO01070231	9/27/01	PCT				
	A02	WO01037819	5/31/01	PCT				
	A03	WO05/041954	5/12/05	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	A04	Adachi et al., 2001, "Indirubins and Indigo are Potent Aryl Hydrocarbon Receptor Ligands Present in Human Urine," <i>The J. of Biol. Chem.</i> , 276(34):31475-31478.
	A05	Fischer et al., 2003, "Cyclin-Dependent Kinase Inhibitors," <i>Progress in Cell Cycle Res.</i> , 5:235-248.
	A06	Knockaert et al., 2004, "Independent Actions on Cyclin Dependent Kinases and Aryl Hydrocarbon Receptor Mediate the Antiproliferative Effects of Indirubins," <i>Oncogene</i> , 23:4400-4412.
	A07	Leclerc et al., 2001, "Indirubins Inhibit Glycogen Synthase Kinase-3beta and CDK5/P25, Two Protein Kinases Involved in Abnormal Tau Phosphorylation in Alzheimer's Disease," <i>The J. of Biol. Chem.</i> , 276(1):251-260.
	A08	Meijer et al., 2003, "GSK-3-Selective Inhibitors Derived From Tyrian Purple Indirubins," <i>Chemistry and Biol.</i> , 10(12):1255-1266.
	A09	Polychronopoulos <i>et al.</i> , 2004, "Structural Basis for the Synthesis of Indirubins as Potent and Selective Inhibitors of Glycogen Synthase Kinase-3 and Cyclin-Dependent Kinases," <i>Journal of Med. Chem.</i> , 47:936-946.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.